



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete If Known

Application Number	10/528611
Filing Date	March 21, 2005
First Named Inventor	STEVEN GUTTERIDGE
Group Art Unit	UNKNOWN 1646
Examiner Name	UNASSIGNED Ruixiang Li
Attorney Docket Number	BB1533USPCT

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)				
/R.L./	1	US - 6,808,873 B2		10-26-2004	MURPHY ET AL.	
/R.L./	2	US - 2001/0046664 A1		11-29-2001	MURPHY ET AL.	
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				
		US -				

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		CountryCode ³	Number ⁴ Kind Code ⁵ (if known)				
/R.L./	1	WO	01/71042 A2	09-27-2001	PE CORPORATION		<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>

Examiner
Signature


/Ruixiang Li/

Date
Considered

09/22/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number	10/528611
Filing Date	March 21, 2005
First Named Inventor	STEVEN GUTTERIDGE ET AL.
Group Art Unit	UNKNOWN 1646
Examiner Name	UNASSIGNED Ruixiang Li
Attorney Docket Number	BB1533USPCT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/R.L./	1	CHRISTOPHER H. GEORGE ET AL., Ryanodine Receptor Mutations Associated With Stress-Induced Ventricular Tachycardia Mediate Increased Calcium Release in Stimulated Cardiomyocytes, Circ. Res. 93:531-540, 2003	<input type="checkbox"/>
	2	KINYA OTSU ET AL., Chromosome Mapping of Five Human Cardiac and Skeletal Muscle Sarcoplasmic Reticulum Protein Genes, Genomics, 17:507-509, 1993	<input type="checkbox"/>
	3	GIUSEPPE GIANNINI ET AL., The Ryanodine Receptor/Calcium Channel Genes are Widely and Differentially Expressed in Murine Brain and Peripheral Tissues, The Journal of Cell Biology, 128(5):893-904, 1995	<input type="checkbox"/>
	4	DAWEI JIANG ET AL., Enhanced Basal Activity of a Cardiac Ca ²⁺ Release channel (Ryanodine Receptor) Mutant Associated with Ventricular Tachycardia and Sudden Death, Circulation Research, 91:218-225, 2002	<input type="checkbox"/>
	5	XUEHONG XU ET AL., Molecular Cloning of cDNA Encoding a Drosophila Ryanodine Receptor and Functional Studies of the Carboxyl-Terminal Calcium Release Channel, Biophysical Journal, 78:1270-1281, 2000	<input type="checkbox"/>
	6	HIROSHI TAKESHIMA ET AL., Ca ²⁺ -induced Ca ²⁺ release in myocytes from dyspedic mice lacking the type-1 ryanodine receptor, The EMBO Journal 14(13):2999-3006, 1995	<input type="checkbox"/>
	7	STEVEN O. MARX ET AL., PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor): Defective Regulation in Failing Hearts, Cell, Vol. 101:365-376, 2000	<input type="checkbox"/>
	8	ANDREW J. DINSMORE ET AL., Characterisation of Antibody Models of the Ryanodine Receptor for Use in High-Throughput Screening, Pestic Sci., Vol. 54:345-352, 1998	<input type="checkbox"/>
	9	TOSHIKI IMAGAWA ET AL., Expression of Ca ²⁺ -induced Ca ²⁺ Release Channel Activity from Cardiac Ryanodine Receptor cDNA in Chinese Hamster Ovary Cells, J. Biochem., Vol. 112:508-513, 1992	<input type="checkbox"/>
↓	10	BARBARA BAUCE ET AL., Screening for Ryanodine Receptor Type 2 Mutations in Families with Effort-Induced Polymorphic Ventricular Arrhythmias and Sudden Death, J. of Amer. Coll. of Card., Vol. 40(2):341-349, 2002	<input type="checkbox"/>
/R.L./	11	GIAN ANTONIO ET AL., Genetics of arrhythmogenic right ventricular cardiomyopathy, Current Opinion in Cardiology, Vol. 17:218-221, 2002	<input type="checkbox"/>

Examiner Signature	/Ruixiang Li/	Date Considered	09/22/2007
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 5

Complete if Known

Application Number	10/528611
Filing Date	March 21, 2005
First Named Inventor	STEVEN GUTTERIDGE ET. AL.
Group Art Unit	UNKNOWN 1646
Examiner Name	UNASSIGNED Ruixiang Li
Attorney Docket Number	BB1533USPCT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/R.L./	12	MIEKO SHIWA ET AL., Molecular Cloning and characterization of ryanodine receptor from unfertilized sea urchin eggs, Am. J. Physiol. Reg. Integrative Comp., Vol. 282:R727-R737, 2002	<input type="checkbox"/>
	13	YASUO OGAWA ET AL., Ryanodine Receptor Isoforms in Excitation-Contraction Coupling, Adv. Biophys., Vol. 26:27-64, 1999	<input type="checkbox"/>
	14	G. LEES ET AL., Cell Culture Approaches to Invertebrae Neuroscience, Academic Press, New York, pp. 123-127, 1988	<input type="checkbox"/>
	15	MANJUNATHA B. BHAT ET AL., Functional Calcium release Channel Formed by the Carboxyl-Terminal Portion of Ryanodine Receptor, Biophysical J., Vol. 73:1329-1336, 1997	<input type="checkbox"/>
	16	NATASCIA TISO ET AL., The binding of the RyR2 calcium channel to its gating protein FKBP12.6 is oppositely affected by ARVD2 and VTSIP mutations, Biochem. & Biophys. Res. Comm., Vol. 229:594-598, 2002	<input type="checkbox"/>
	17	ISAAC N. PESSAH ET AL., Calcium-Ryanodine Receptor Complex, The J. of Biol. Chem., Vol. 261(19):8643-8648, 1986	<input type="checkbox"/>
	18	ELISABETH LEHMBERG ET AL., Similarity of Insect and Mammalian Ryanodine Binding Sites, Pesticide Biochem. & Phys., Vol. 48:145-152, 1994	<input type="checkbox"/>
	19	HIROSHI TAKESHIMA ET AL., Isolation and characterization of a gene for a ryanodine receptor/calcium release channel in Drosophila melanogaster, FEBS Letters, Vol. 337:81-87, 1994	<input type="checkbox"/>
	20	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 456161, ACC. NO. D17389, 3/25/1999, H. TAKESHIMA ET AL., Isolation and characterization of a gene for a ryanodine receptor/calcium release channel in Drosophila melanogaster	<input type="checkbox"/>
↓	21	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 1871446, ACC. NO. D45899, 12/25/2002, Y. SAKUBE ET AL., An abnormal ketamine response in mutants defective in the ryanodine receptor gene ryr-1 (unc-68) of Caenorhabditis elegans	<input type="checkbox"/>
/R.L./	22	YASUJI SAKUBE ET AL., An Abnormal ketamine Response in Mutants Defective in the Ryanodine Receptor Gene ryr-1 (unc-68) of Caenorhabditis elegans, J. Mol. Biol., Vol. 267:849-864, 1997	<input type="checkbox"/>

Examiner
Signature

/Ruixiang Li/

Date
Considered

09/22/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/528811
Filing Date	March 21, 2005
First Named Inventor	STEVEN GUTTERIDGE ET. AL.
Group Art Unit	UNKNOWN 1646
Examiner Name	UNASSIGNED Ruixiang Li
Attorney Docket Number	BB1533USPCT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/R.L./	23	ELENA PUENTE ET AL., Identification of a polymorphic ryanodine receptor gene from <i>Heliothis virescens</i> (Lepidoptera: Noctuidae), Insect Biochem. & Mol. Biol., Vol. 30:335-347, 2000	<input type="checkbox"/>
	24	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 17352471, ACC. NO. 476994, 12/10/2003, M. D. ADAMS ET AL., The genome sequence of <i>Drosophila melanogaster</i>	<input type="checkbox"/>
	25	MARK D. ADAMS ET AL., The genome sequence of <i>Drosophila melanogaster</i> , Vol. 287:2185-2195, 2000	<input type="checkbox"/>
	26	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 21301556, ACC. NO. EAA17301, 5/31/2002	<input type="checkbox"/>
	27	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 1871447, ACC. NO. BAA08309, 12/25/2002, Y. SAKUBE ET AL., An abnormal ketamine response in mutants defective in the ryanodine receptor gene <i>ryr-1</i> (unc-68) of <i>Caenorhabditis elegans</i>	<input type="checkbox"/>
	28	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 18858155, ACC. NO. BAB84714, 2/14/2002, M. SHIWA ET AL., Molecular cloning and characterization of ryanodine receptor from unfertilized sea urchin eggs	<input type="checkbox"/>
	29	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 13569850, ACC. NO. NP076357, 12/21/2003, H. MASUMIYA ET AL., The mouse sino-atrial node expresses both the type 2 and type 3 (Ca ²⁺) release channels/ryanodine receptors	<input type="checkbox"/>
	30	HARUKO MASUMIYA ET AL., The mouse sino-atrial node expresses both the type 2 and type 3 (Ca ²⁺) release channels/ryanodine receptors, Febs Letters, Vol. 553:141-144, 2003	<input type="checkbox"/>
	31	PATRICK MOST ET AL., Transgenic Overexpression of the Ca ²⁺ -binding Protein S100A1 in the Heart Leads to Increased in Vivo Myocardial Contractile Performance, J. of Biol. Chem., Vol. 278(36):33809-33817, 2003	<input type="checkbox"/>
↓	32	HUANG-TIAN YANG ET AL., The ryanodine receptor modulates the spontaneous beating rate of cardiomyocytes during development, PNAS, Vol. 99(14):9225-9230, 2002	<input type="checkbox"/>
/R.L./	33	ANNE-VALERIE FAURE ET AL., Developmental expression of the calcium release channels during early neurogenesis of the mouse cerebral cortex, European J. of Neuroscience, Vol. 14:1613-1622, 2001	<input type="checkbox"/>

Examiner Signature	/Ruixiang Li/	Date Considered	09/22/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 5

Complete If Known

Application Number	10/528611
Filing Date	March 21, 2005
First Named Inventor	STEVEN GUTTERIDGE ET. AL.
Group Art Unit	UNKNOWN 1646
Examiner Name	UNASSIGNED Ruixiang Li
Attorney Docket Number	BB1533USPCT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/R.L./	34	MINGCAI ZHAO ET AL., Molecular identification of the Ryanodine Receptor Pore-forming Segment, J. of Biol. Chem., Vol. 274(37):25971-25974, 1999	<input type="checkbox"/>
	35	HIROSHI TAKESHIMA ET AL., Embryonic lethality and abnormal cardiac myocytes in mice lacking ryanodine receptor type 2, The EMBO J., Vol. 17(12):3309-3318, 1998	<input type="checkbox"/>
	36	NATIONAL CENTER FOR BIOTECHNOLOGY GENERAL IDENTIFIER NO. 1245376, ACC. NO. AAA93465, 4/2/1996, J. NAKAI ET AL., Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel	<input type="checkbox"/>
	37	JUNICHI NAKAI ET AL., Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel, FEBS, Vol. 271(1,2):169-177, 1990	<input type="checkbox"/>
	38	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 4506757, ACC. NO. NP001026, 12/23/2003, C.H. GEORGE ET AL., Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes	<input type="checkbox"/>
	39	CHRISTOPHER H. GEORGE ET AL., Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes, J. of Biol. Chem., Vol. 278(31):28856-28864, 2003	<input type="checkbox"/>
	40	JING ZHANG ET AL., Three-dimensional Localization of Divergent Region 3 of the Ryanodine Receptor to the Clamp-shaped Structures Adjacent to the FKBP Binding Sites, J. Biol. Chem., Vol. 278(16):14211-14218, 2003	<input type="checkbox"/>
	41	HARUKO MASUMIYA ET AL., Localization of the 12.6-kDa FK506-binding Protein (FKBP12.6) Binding Site to the NH2-terminal Domain of the Cardiac Ca2+ Release Channel (Ryanodine Receptor), J. Biol. Chem., Vol. 278(6):3786-3792, 2003	<input type="checkbox"/>
	42	JIEFEI TONG ET AL., Caffeine and Halothane Sensitivity of Intracellular Ca2+ Release is Altered by 15 Calcium Release Channel (Ryanodine Receptor) Mutations Associated with Malignant Hyperthermia and/or Central Core Disease, J. Biol. Chem., Vol. 272(42):26332-26339, 1997	<input type="checkbox"/>
↓	43	S. R. WAYNE CHEN ET AL., Antibodies as Probes for Ca2+ Activation Sites in the Ca2+ Release Channel (Ryanodine Receptor) of Rabbit Skeletal Muscle Sarcoplasmic Reticulum, J. Biol. Chem., Vol. 268(18):13414-13421, 1993	<input type="checkbox"/>
/R.L./	44	CELETTA CALLWAY ET AL., Localization of the High and Low Affinity [3H]Ryanodine binding Sites on the Skeletal Muscle Ca2+ Release Channel, J. Biol. Chem., Vol. 269(22):15876-15884, 1994	<input type="checkbox"/>

Examiner Signature	/Ruixiang Li/	Date Considered	09/22/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	10/528611
Filing Date	March 21, 2005
First Named Inventor	STEVEN GUTTERIDGE ET. AL.
Group Art Unit	UNKNOWN 1646
Examiner Name	UNASSIGNED Ruixiang Li
Attorney Docket Number	BB1533USPCT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/R.L./	45	MELANIE SCHMITT ET AL., Binding Sites for Ca ²⁺ -Channel Effectors and Ryanodine in Periplaneta americana - Possible Targets for New Insecticides, Pestic Science, Vol. 48:375-385, 1996	<input type="checkbox"/>
/R.L./	46	RICHARD E.A. TUNWELL ET AL., The human cardiac muscle ryanodine receptor-calcium release channel: identification, primary structure and topological analysis, Biochem. J. Vol. 318:477-487, 1996	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature	/Ruixiang Li/	Date Considered	09/22/2007
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.